Last Updated on October 6, 2024 by The Health Master
New Delhi: Daiichi Sankyo said the U.S. health regulator has approved its drug for treating newly diagnosed patients suffering from an aggressive type of blood cancer, pitting the treatment against those from rivals Novartis and Astellas.
The drug, which is already approved in Japan has faced a long path to the U.S. market, with the U.S. Food and Drug Administration (USFDA) declining to approve it in 2019 in a different set of acute myeloid leukemia (AML) patients and then extending its review by three months earlier this year.
The treatment, branded as Vanflyta, got USFDA’s nod to treat adult patients with a specific gene mutation associated with increased risk of relapse in patients with AML, a type of blood and bone marrow cancer.
The wholesale acquisition cost of the treatment is $546 per tablet for both the 17.7 mg and 26.5 mg dose, the company said on Thursday.
Astellas’ oral tablet Xospata’s wholesale acquisition cost is $22,500 for a month’s supply, while the list price of Novartis’ Rydapt is $7,495 for a 14-day treatment and $14,990 for a 28-day treatment.
Daiichi has been focusing on building its oncology portfolio to help drive growth.
“It’s the biggest growth area of Daiichi Sankyo, and we’re off to a really, really strong start,” Ken Keller, head of the company’s global oncology business said ahead of the approval.
Jefferies analyst Naoya Miura expects the drug to make $500 million in sales after 10 years.
AML is one of the most common types of blood cancer in adults. Mutations in the FLT3 gene, which plays a role in helping white blood cells grow, can cause excess growth of these cells and lead to an aggressive form of leukemia.
Patients with the FLT3-ITD mutation, which is targeted by Daiichi’s drug, are at an increased risk of relapse and shorter survival.
USFDA approves this drug to prevent RSV in babies and toddlers
USFDA gives approval for Chlorpromazine HCL tablets
USFDA gives approval for OTC Acetaminophen and Ibuprofen Tablets
USFDA gives tentative nod for Dolutegravir tablets for oral suspension
FDCs Ban case: Delhi High Court grants time for Centre and Pharma Companies to Submit Affidavits
Indian Pharma Industry wants to end multiple inspections by USFDA
Govt asks Medical Stores not to sell painkillers without prescription: Delhi
DCGI plans unified Online Portal for Drug Quality and Patient Safety
Committee asks USFDA to submit details on inspection of Pharma Companies in India and China
AHUs, Air Types, Air Changes and their Functions in Pharma Industry
Third Phase of Risk Based Inspections on Pharma Companies concluded: Gujarat
Pharmacy Council appoints four Pharmacy Inspectors: Karnataka
Drug alert: DCGI issues drug alert on usage of cough and cold medicine
Govt Job: for the post of Director at CDTL – Central Drugs Testing Laboratory
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
